MNKD
HealthcareMannKind Corporation
$5.62
+$0.02 (+0.36%)
Jan 5, 2026
Price History (1Y)
Analysis
MannKind Corporation is a biotechnology company in the healthcare sector. It has a market capitalization of $1.73B and annual revenues of $313.79M, employing 403 individuals. The company operates within the biotechnology industry. The company's financial health indicates moderate profitability with gross margins at 75.2%, operating margins at 22.9%, and profit margins at 9.3%. Return on Assets (ROA) is 9.9% while free cash flow is $29.33M. MannKind Corporation has a cash balance of $260.04M against debt of $225.43M, resulting in a current ratio of 3.29. The company's valuation multiples are relatively high with a P/E Ratio (TTM) of 56.20 and forward P/E of 38.32. Revenue growth is at 17.2% year-over-year while earnings growth has been negative at -34.9%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Visit website →Key Statistics
- Market Cap
- $1.73B
- P/E Ratio
- 56.20
- 52-Week High
- $6.43
- 52-Week Low
- $3.38
- Avg Volume
- 3.88M
- Beta
- 0.81
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 403